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LETTER TO THE EDITOR
How nephrotoxic is carboplatin?
Sir - The study by Sleijfer et al. (1989) reports on a
significant deterioration in renal function following moderate
dose carboplatin - with a 19% reduction in glomerular filtra-
tion rate. This raises reservations about the claimed advan-
tages of carboplatin over cisplatin and suggests that not only
is close monitoring of renal function necessary, but also that
hyperhydration regimens should be considered. Should this
be true, one of the major benefits of carboplatin, namely its
convenient administration at standard dose in an outpatient
setting, would disappear.
We have reviewed the data on 28 patients given high dose
carboplatin as a single agent for ovarian cancer in whom
sequential glomerular filtration rate (GFR) assessments were
determined before, during and after carboplatin therapy.
Patients were aged 33-66 years (median 55 years) with
stage III and IV disease. No patient had received prior
chemotherapy. Carboplatin was administered as a one hour
infusion, at an initial dose of 1 g m-2 in 500 ml 5% dextrose
with no extra hydration. This dose was reduced in subse-
quent courses if unacceptable myelosuppression was seen in
course 1. The median number of courses given was 4 (range
1-5). Baseline serum urea, creatinine and electrolytes were
normal in all cases. GFR was determined before treatment
using 5"Cr-ethylenediamine tetraacetic acid (EDTA), the
GFR being calculated from the plasma decay curve using
three data points as described by Chantler et al. (1969). GFR
estimates were made before each treatment course. In 18
patients a 'follow-up' GFR was estimated > 3 months after
cessation of carboplatin. The median EDTA clearances
before, immediately following and >3 months following
chemotherapy were 80.5 ml min-' (range 46-115),
66.0 ml min-' (range 36-1 10) and 82.0 ml min-' (range
50-140) respectively. The median reduction in EDTA follow-
ing treatment was 12.5 ml min -. There was a significant
difference between the pre- and post-treatment median
EDTAs (P <0.0001) but no difference between the pre- and
follow-up median EDTAs (Wilcoxon one-sided test of
difference).
As shown in Figure 1, it is clear that at this high dose of
carboplatin there is a decline in GFR in most patients. This
was to be anticipated from the original phase 1 studies by
Gore et al. (1987), where dose limiting nephrotoxicity occur-
red to some extent at all doses > 800 mg m-2. The important
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Figure 1 5"Cr-EDTA glomerular filtration rates before,
immediately following and > 3 months following high-dose
carboplatin. , median values.
finding in this study is that even at high dose this seems to beJ
a transient phenomenon, in that recovery occurred in most
patients subsequently studied. This is in contrast to the
nephrotoxicity of cisplatin where little, if any, recovery can
be expected (Daugaard et al., 1988).
It is essential that studies evaluating the nephrotoxicity of
platinum analogues use sensitive measures of GFR and do
not rely on crude indicators such as serum creatinine, as has
been a tendency in the past. However, with more sensitive
techniques it is important that over-interpretation is avoided.
While the transient decline in GFR seen with high dose
carboplatin should lead to caution in the use of other
nephrotoxic drugs such as the aminoglycosides, there is no
indication that inconvenient hyperhydration regimens or
extra monitoring of GFR is required. Moreover, at the lower
doses of carboplatin normally used (i.e. 300-500 mg m-2)
sequential GFR estimates have failed to show any significant.
decline (Tait et al., 1988; Calvert et al., 1985).
Yours etc.,
J.R. Hardy, S. Tan, I. Fryatt & E. Wiltshaw
Gynaecology Unit, Royal Marsden Hospital,
London SW3 6JJ, UK.
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